Cresco Labs Inc. (OTCMKTS:CRLBF) Receives $2.50 Average Price Target from Brokerages

by · The Cerbat Gem

Cresco Labs Inc. (OTCMKTS:CRLBF – Get Free Report) has been assigned an average rating of “Buy” from the six research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $2.50.

Several research firms have recently commented on CRLBF. Needham & Company LLC restated a “hold” rating on shares of Cresco Labs in a research note on Monday, August 12th. Ventum Cap Mkts raised Cresco Labs to a “strong-buy” rating in a report on Friday, August 9th. Finally, Roth Capital raised Cresco Labs from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 9th.

Read Our Latest Research Report on CRLBF

Cresco Labs Price Performance

OTCMKTS CRLBF opened at $1.64 on Friday. The company has a 50-day moving average price of $1.66 and a 200-day moving average price of $1.82. Cresco Labs has a 52 week low of $1.06 and a 52 week high of $2.65. The company has a quick ratio of 1.30, a current ratio of 2.00 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $800.55 million, a P/E ratio of -3.49 and a beta of 1.86.

Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.15). Cresco Labs had a negative net margin of 23.07% and a negative return on equity of 17.03%. The business had revenue of $184.36 million for the quarter, compared to the consensus estimate of $184.26 million. Equities research analysts anticipate that Cresco Labs will post -0.15 earnings per share for the current year.

Cresco Labs Company Profile

(Get Free Report

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.

See Also